The purpose of this study was to evaluate whether the membrane type 1 matrix metalloproteinase-14 (or MT1-MMP) tissue expression, as assessed visually on digital slides and by digital image analysis, could predict outcomes in women with ovarian carcinoma. Tissue microarrays from a cohort of 211 ovarian carcinoma women who underwent a debulking surgery between 1993 and 2006 at the CHU de Québec (Canada) were immunostained for matrix metalloproteinase-14. The percentage of MMP-14 staining was assessed visually and with the Calopix software. Progression was evaluated using the CA-125 and/or the RECIST criteria according to the GCIG criteria. Dates of death were obtained by record linkage with the Qué bec mortality files. Adjusted hazard ratios of death and progression with their 95% confidence intervals were estimated using the Cox model. Comparisons between the two modalities of MMP-14 assessment were done using the box plots and the Kruskal-Wallis test. The highest levels of MMP-14 immunostaining were associated with nonserous histology, early FIGO stage, and low preoperative CA-125 levels (Po0.05). In bivariate analyses, the higher level of MMP-14 expression (440% of MMP-14-positive cells) was inversely associated with progression using visual assessment (hazard ratio ¼ 0.39; 95% confidence interval: 0.18-0.82). A similar association was observed with the highest quartile of MMP-14-positive area assessed by digital image analysis (hazard ratio ¼ 0.48; 95% confidence interval: 0.28-0.82). After adjustment for standard prognostic factors, these associations were no longer significant in the ovarian carcinoma cohort. However, in women with serous carcinoma, the highest quartile of MMP-14-positive area was associated with progression (adjusted hazard ratio ¼ 0.48; 95% confidence interval: 0.24-0.99). There was no association with overall survival. The digital image analysis of MMP-14-positive area matched the visual assessment using three categories (440% vs 21-40 vs o20%). Higher levels of MMP-14 immunostaining were associated with standard factors of better ovarian carcinoma prognosis. In women with serous carcinoma, high expression of MMP-14 was associated with lower progression. Modern Pathology (2014Pathology ( ) 27, 1394Pathology ( -1404 doi:10.1038/modpathol.2014 published online 7 March 2014 Keywords: digital image analysis; immunohistochemistry; matrix metalloproteinase-14; ovarian carcinoma; prognosisIn the western world, ovarian cancer is the leading cause of death among gynecological malignancies and the fifth leading cause of cancer death. 1-3 Most patients present with advanced stage disease, partly because of its anatomic location, nonspecific symptoms, and lack of reliable screening methods. Despite a high rate of complete remission rate after radical surgery followed by taxane and platinumbased chemotherapy, relapse occurs in the majority